C. Gabay
Annals of the Rheumatic Diseases · 2006–2013
A researcher in the Science corpus: 6 papers; trusts 0 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Who trusts C. Gabay overall
Papers from C. Gabay's perspective
Ordered by how strongly the researchers C. Gabay trusts endorse each paper. Same corpus, a different order for every researcher.
- IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. (Immunity)
- Cryopyrin activates the inflammasome in response to toxins and ATP (Nature)
- NLRs join TLRs as innate sensors of pathogens. (Trends in immunology)
- Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo (Nature Medicine)
- Gout-associated uric acid crystals activate the NALP3 inflammasome (Nature)
- A pilot study of IL-1 inhibition by anakinra in acute gout (Arthritis Research & Therapy)
- The role of inflammation in CNS injury and disease (British Journal of Pharmacology)
- Interleukin 1 in the brain: biology, pathology and therapeutic target. (Trends in Neurosciences)
- Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice (Journal of Experimental Medicine)
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled… (Annals of the Rheumatic Diseases)
Their papers
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) — 4,103 citations
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. (2013) — 672 citations
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (2012) — 14,291 citations
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) — 2,684 citations
- IL‐1, IL‐18, and IL‐33 families of cytokines (2008) — 888 citations
- Interleukin-6 and chronic inflammation (2006) — 1,438 citations